Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptor, Fibroblast Growth Factor, Type 3”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT07393373
What this trial is testing

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 135
Large-scale testing (Phase 3)Study completedNCT03410693
What this trial is testing

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional Cell
Bayer 175
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Large-scale testing (Phase 3)Study completedNCT06164951
What this trial is testing

Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 114
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Large-scale testing (Phase 3)Enrolling By InvitationNCT06873035
What this trial is testing

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 24
Large-scale testing (Phase 3)Ended earlyNCT03773302
What this trial is testing

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827612
What this trial is testing

Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUrologic NeoplasmsReceptor, Fibroblast Growth Factor, Type 3
Eli Lilly and Company 161
Not applicableAvailableNCT07675057
What this trial is testing

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05145010
What this trial is testing

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 300
Early research (Phase 1)Study completedNCT02529553
What this trial is testing

LY3076226 in Participants With Advanced or Metastatic Cancer

Who this might be right for
Advanced CancerMetastatic Cancer
Eli Lilly and Company 25
Testing effectiveness (Phase 2)Study completedNCT04265651
What this trial is testing

Study of Infigratinib in Children With Achondroplasia

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 84
Testing effectiveness (Phase 2)Ended earlyNCT05363605
What this trial is testing

[225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorHead and Neck Squamous Cell CarcinomaBladder Carcinoma+11 more
Fusion Pharmaceuticals Inc. 6
Not applicableLooking for participantsNCT06410976
What this trial is testing

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 150
Testing effectiveness (Phase 2)Looking for participantsNCT07169279
What this trial is testing

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 77
Large-scale testing (Phase 3)Ended earlyNCT03656536
What this trial is testing

Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Who this might be right for
Unresectable CholangiocarcinomaMetastatic Cholangiocarcinoma
Incyte Corporation 167